New Alpha-Particle drug targets Hard-to-Treat thyroid cancer

NCT ID NCT07287748

Recruiting now Disease control Sponsor: Alpha Fusion Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new radioactive drug called Af-001 in people with advanced differentiated thyroid cancer that cannot be removed by surgery or has spread. The study has two parts: first, to find the safest dose, and second, to see if multiple doses can shrink tumors. About 38 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Af-001 (a radioactive drug that emits alpha particles)
What this could lead to: If successful, this could provide a new treatment option for people with advanced thyroid cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 38 participants, so safety and effectiveness are not yet proven. The radioactive drug may cause serious side effects like low blood counts or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DTC - DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma papillary carcinoma thyroid gland follicular carcinoma thyroid gland papillary carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DTC - DIFFERENTIATED THYROID CANCER

Contacts and locations

Locations

National Cancer Center Hospital East
RECRUITING

Kashiwa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.